...portfolio companies —AlloVir Inc. (NASDAQ:ALVR) and HighPassBio...

...subsidiary. ElevateBio has disclosed relationships with two -- antiviral play AlloVir and blood cancer company HighPassBio...
...develop a T cell therapy for immunocompromised patients who are at risk of developing COVID-19. HighPassBio...
...to treat and prevent relapse after hematopoietic stem cell transplant (HSCT) in leukemia patients (see “HighPassBio...

...HighPassBio and antiviral play AlloVir have since emerged as ElevateBio portfolio companies (see "ElevateBio Launches HighPassBio"...

...Less than five months after its launch, ElevateBio has announced a second portfolio company: HighPassBio, which...
...is developing T cell immunotherapies based on research from the Fred Hutchinson Cancer Research Center. HighPassBio’s...
...to ClinicalTrials.gov, the trial is expected to enroll 24 patients and complete in October 2020. HighPassBio...